CSII
$40.21
Cardiovascular Syst
($2.37)
(5.57%)
CSII
Earnings Whisper ®
N/A
3rd Quarter March 2020
Consensus:  $0.00
Revenue:  $71.53 Mil
Wednesday
May 6
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CSII reports earnings?
Beat
Meet
Miss

Where is CSII's stock price going from here?
Up
Flat
Down
Stock chart of CSII
Analysts
Summary of analysts' recommendations for CSII
Score
Grade
Pivots
Resistance
$44.23
$43.33
$41.77

$40.87

Support
$39.31
$38.41
$36.85
Tweet
Growth
Description
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360? Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360? removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its orbital technology to address the growing market need of providing a safer more effective atherectomy device.
Peers
StrykerBoston ScientificBecton, DickinsonWatersAbbott LaboratoriesBaxter InternationalTeleflex3MIntegra LifeSciences HoldingsResMed